Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) finished Thursday with a subtraction of -$0.81 to close at $8.57, a downside of -8.64 percent. An average of 4,114,340 shares of common stock have been traded in the last five days. There was a fall of -$0.21 in the past week, and it reached a new high 12 times over the past 12 months. The last 20 days have seen an average of 4,406,810 shares traded, while the 50-day average volume stands at 6,999,012.
RXRX stock has decreased by -37.12% in the last month. The company shares reached their 1-month lowest point of $8.36 on 08/21/23. With the stock rallying to its 52-week high on 07/19/23, shares of the company touched a low of $4.54 and a high of $16.75 in 52 weeks. It has reached a new high 14 times so far this year and achieved 11.15% or $0.86 in price. In spite of this, the price is down -48.82% from the 52-week high.
Insider Transactions
RXRX stock investors should be aware that Recursion Pharmaceuticals Inc. (RXRX) stock had its last reported insider trading activity 3 days ago on Aug 22. In this transaction, the insider spent $79,181. Chief Financial Officer, Secora Michael, disposed of 25,000 shares at a price of $8.90 on Aug 16. The insider now owns more than $222,518 worth of shares. Prior to that, Chief Financial Officer Secora Michael went on to Sale 25,000 shares at $9.27 each on Aug 15. An amount of $231,792 was transacted.
Valuation Metrics
Recursion Pharmaceuticals Inc. (RXRX) stock’s beta is 0.01. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 37.13, the price-to-book (PB) ratio at 3.59.
Financial Health
The quick ratio of Recursion Pharmaceuticals Inc. for the three months ended June 29 was 3.80, and the current ratio was 3.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Recursion Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -567.83%. Its gross profit as reported stood at -$8.43 million compared to revenue of $39.84 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Recursion Pharmaceuticals Inc.’s return on assets was -39.90%.
Earnings Surprise
For the three-month period that ended June 29, Recursion Pharmaceuticals Inc. had $1.16 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$76.73 million in the quarter, while revenues of -$65.33 million were grew 14.56%. The analyst consensus anticipated Recursion Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.37 per share, but it turned out to be -$0.38, a -2.70% surprise. For the quarter, EBITDA amounted to -$76.17 million. Shareholders own equity worth $215.59 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Recursion Pharmaceuticals Inc. (RXRX) price momentum. RSI 9-day as of the close on 24 August was 32.31%, suggesting the stock is Neutral, with historical volatility in this time frame at 61.76%.
As of today, RXRX’s price is $8.89 -2.39% or -$0.21 from its 5-day moving average. RXRX is currently trading -33.62% lower than its 20-day SMA and +28.49% higher than its 100-day SMA. However, the stock’s current price level is -13.78% below the SMA50 and -11.10% below the SMA200.
The stochastic %K and %D were 14.26% and 12.97%, respectively, and the average true range (ATR) was 0.90. With the 14-day stochastic at 5.26% and the average true range at 1.00, the RSI (14) stands at 37.54%. The stock has reached 0.07 on the 9-day MACD Oscillator while the 14-day reading was at -0.53.
Analyst Ratings
Morgan Stanley launched coverage on Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) in its analyst report released on May 22, 2023. The firm assigned the stock an Equal-weight rating. The consensus rating for Recursion Pharmaceuticals Inc. (RXRX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RXRX, while 5 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is RXRX’s price target for the next 12 months?
Analysts predict a range of price targets between $9.00 and $35.00, with a median target of $12.50. Taking a look at these predictions, the average price target given by analysts for Recursion Pharmaceuticals Inc. (RXRX) stock is $15.13.
